Work

Therapy of Mucormycosis

Year: 2018

Type: article

Abstract: Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.

Source: Journal of Fungi

DOI: 10.3390/jof4030090

Authors: Nikolaos V. Sipsas, Maria N. Gamaletsou, Amalia Anastasopoulou, Dimitrios P. Kontoyiannis

Institutions: National and Kapodistrian University of Athens, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,137